Press

May 16, 2019

 

”After almost a year at Acarix, I am truly inspired by the opportunities our products offer to revolutionize heart diagnosis. We participate actively in congresses and scientific conferences and see that the need for precise tools to make quick and appropriate decisions continues to grow. Acarix has an important role to play in fulfilling that need.”

– Extract from CEO Per Persson’s commentary to the Interim Report.

First quarter 2019 compared with same period 2018

  • During the first quarter, sales amounted to five CADScor®System and 640 patches compared with four CADScor®System and 520 patches in same period previous year.
  • Revenue amounting to 299 kSEK (230), with gross profit of 209 kSEK (158) and a gross margin of 70% (69).
  • Operational costs amounting 13 038 kSEK (8 170).
  • Result before tax amounted to –12 822 kSEK (–7 963).
  • Net cash flow from operating activities amounted to –13 101 kSEK (–9 444).
  • Basic earnings per share amounted to –0.56 SEK (–0.35). No dilution arose.

Events in the first quarter, 2019
In February Acarix announced that filing for German reimbursement will go directly with the Federal Joint Committee (G-BA) for its CADScor®System. Previously, Acarix was aiming for full reimbursement in Germany by the end of 2019, after initial discussions with relevant associations. However, a new legislation is underway which will impact the local reimbursement process and result in delays. Furthermore, private reimbursement is not affected by the above changes.

Events after March 31, 2019
No major events occurred after March 31, 2019.
The complete interim report is available by link below or on www.acarix.com

For further information, please contact:
Per Persson, CEO
E-mail: per.persson@acarix.com
Phone: +46 736 005 990

Christian Lindholm, CFO
E-mail: christian.lindholm@acarix.com
Phone: +46 705 118 333

Interim Report, January – March 2019

About Acarix
Acarix is a Swedish medical device company that innovates solutions for rapid AI-based rule out of Coronary Artery Disease (CAD). The CE approved and FDA DeNovo cleared Acarix CADScor®System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive and costly diagnostic procedures. The CADScor system calculates a patient-specific CAD-score non-invasively in less than10 minutes and can help rule out more than one third of patients with at least 96% certainty of not being sick (in a population with approx. 10% CAD prevalence). Acarix is listed on the Nasdaq First North Premier Growth Market (ticker: ACARIX). Redeye AB (+46 (0)8 121 576 90, certifiedadviser@redeye.se) is Certified Advisor of Acarix.

For more information, please visit www.acarix.com.